Designing allosteric activators of CSE as novel oral inhibitors of pathologic calcification

Forschungsstelle

INNOSUISSE

Projektnummer

124.461 IP-LS

Projekttitel

Designing allosteric activators of CSE as novel oral inhibitors of pathologic calcification

Projekttitel Englisch

Designing allosteric activators of CSE as novel oral inhibitors of pathologic calcification

Texte zu diesem Projekt

	Deutsch	Französisch	Italienisch	Englisch
Schlüsselwörter	-	-	-
Abstract	-	-	-

Kategorie	Text
Schlüsselwörter (Englisch)	Life sciences, Pharmaceuticals
Abstract (Englisch)	SULFISCON is developing small molecule activators of the enzyme CSE to modulate endogenous H2S production as a drug. We seek support to optimise pharmacologic properties of current lead compounds for oral administration and test their effects in animal models of pathologic calcification.